ArticleJournal of the National Cancer Institute2009
Effect of lapatinib on the development of estrogen receptor-negative mammary tumors in mice.
Article in Journal of the National Cancer Institute, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 48 citations in OpenAlex.
- Lapatinib mitigates acetic acid-induced ulcerative colitis and hepatic damage in rats.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Gross tumor assessment is not a reliable measure of the efficacy of chemo-preventive agents for breast cancer in preclinical mouse models.Scientific reports · 2025Article
- Dual inhibition of HERs and PD-1 counteract resistance in KRASJournal of experimental & clinical cancer research : CR · 2024Article
- Activation of Neuregulin 1/ErbB Signaling Is Involved in the Development of TOCP-Induced Delayed Neuropathy.Frontiers in molecular neuroscience · 2018Article
- Targeting Aberrant p70S6K Activation for Estrogen Receptor-Negative Breast Cancer Prevention.Cancer prevention research (Philadelphia, Pa.) · 2017Article
- Short-term early exposure to lapatinib confers lifelong protection from mammary tumor development in MMTV-erbB-2 transgenic mice.Journal of experimental & clinical cancer research : CR · 2017Article
- HER2 and EGFR Overexpression Support Metastatic Progression of Prostate Cancer to Bone.Cancer research · 2017Article
- The hallmarks of premalignant conditions: a molecular basis for cancer prevention.Seminars in oncology · 2016Review
- Downregulation of GLUT4 contributes to effective intervention of estrogen receptor-negative/HER2-overexpressing early stage breast disease progression by lapatinib.American journal of cancer research · 2016Article
- Women's Expectations for Breast Cancer Prevention and Early Detection: High Expectations Can Be Achieved.The oncologist · 2016Article
- Targeting HER2 Positive Breast Cancer with Chemopreventive Agents.Current pharmacology reports · 2015Article
- Assay of lapatinib in murine models of cigarette smoke carcinogenesis.Carcinogenesis · 2014Article
- Advances in Preventive Therapy for Estrogen-Receptor-Negative Breast Cancer.Current breast cancer reports · 2014Review
- A multiantigen vaccine targeting neu, IGFBP-2, and IGF-IR prevents tumor progression in mice with preinvasive breast disease.Cancer prevention research (Philadelphia, Pa.) · 2013Article
- Targeted therapy for breast cancer prevention.Frontiers in oncology · 2013Review
- Oral administration of a gemini vitamin D analog, a synthetic triterpenoid and the combination prevents mammary tumorigenesis driven by ErbB2 overexpression.Cancer prevention research (Philadelphia, Pa.) · 2013Article
- The invisible arm of immunity in common cancer chemoprevention agents.Cancer prevention research (Philadelphia, Pa.) · 2013Review
- LOXL2 induces aberrant acinar morphogenesis via ErbB2 signaling.Breast cancer research : BCR · 2013Article
- RKI-1447 is a potent inhibitor of the Rho-associated ROCK kinases with anti-invasive and antitumor activities in breast cancer.Cancer research · 2012Article
- SLC22A5/OCTN2 expression in breast cancer is induced by estrogen via a novel intronic estrogen-response element (ERE).Breast cancer research and treatment · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 3 institutions in 2 countries.
Funding
Abstract
Lapatinib, a selective orally available inhibitor of epidermal growth factor receptor (EGFR) and ErbB2 receptor tyrosine kinases, is a promising agent for the treatment of breast cancer. We examined the effect of lapatinib on the development of mammary tumors in MMTV-erbB2 transgenic mice, which express wild-type ErbB2 under the control of the mouse mammary tumor virus promoter and spontaneously develop estrogen receptor (ER)-negative and ErbB2-positive mammary tumors by 14 months of age. Mice were treated from age 3 months to age 15 months with vehicle (n = 17) or lapatinib (30 or 75 mg/kg body weight; n = 16 mice per group) by oral gavage twice daily (6 d/wk). All statistical tests were two-sided. By 328 days after the start of treatment, all 17 (100%) of the vehicle-treated mice vs five (31%) of the 16 mice treated with high-dose lapatinib developed mammary tumors (P < .001). Among MMTV-erbB2 mice treated for 5 months (n = 20 mice per group), those treated with lapatinib had fewer premalignant lesions and noninvasive cancers in their mammary glands than those treated with vehicle (P = .02). Lapatinib also effectively blocked epidermal growth factor-induced signaling through the EGFR and ErbB2 receptors, suppressed cyclin D1 and epiregulin mRNA expression, and stimulated p27 mRNA expression in human mammary epithelial cells and in mammary epithelial cells from mice treated for 5 months with high-dose lapatinib. Thus, cyclin D1, epiregulin, and p27 may represent useful biomarkers of lapatinib response in patients. These data suggest that lapatinib is a promising agent for the prevention of ER-negative breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.